These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3873217)

  • 1. Activation of normal and abnormal human factor IX with trypsin.
    Monroe DM; Noyes CM; Straight DL; Roberts HR; Griffith MJ
    Arch Biochem Biophys; 1985 May; 238(2):490-6. PubMed ID: 3873217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivity of bovine blood coagulation factor IXa beta, factor Xa beta, and factor XIa toward fluorogenic peptides containing the activation site sequences of bovine factor IX and factor X.
    Castillo MJ; Kurachi K; Nishino N; Ohkubo I; Powers JC
    Biochemistry; 1983 Mar; 22(5):1021-9. PubMed ID: 6601494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
    Griffith MJ; Breitkreutz L; Trapp H; Briet E; Noyes CM; Lundblad RL; Roberts HR
    J Clin Invest; 1985 Jan; 75(1):4-10. PubMed ID: 3871202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
    Noyes CM; Griffith MJ; Roberts HR; Lundblad RL
    Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4200-2. PubMed ID: 6603618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.
    Chung KS; Madar DA; Goldsmith JC; Kingdon HS; Roberts HR
    J Clin Invest; 1978 Nov; 62(5):1078-85. PubMed ID: 711853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
    McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
    Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme.
    Lenting PJ; ter Maat H; Clijsters PP; Donath MJ; van Mourik JA; Mertens K
    J Biol Chem; 1995 Jun; 270(25):14884-90. PubMed ID: 7797466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavage and inactivation of Factor IX by granulocyte elastase.
    Takaki A; Enfield DL; Thompson AR
    J Clin Invest; 1983 Nov; 72(5):1706-15. PubMed ID: 6605369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.
    Lenting PJ; Christophe OD; Maat H; Rees DJ; Mertens K
    J Biol Chem; 1996 Oct; 271(41):25332-7. PubMed ID: 8810297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of lipid binding and kinetic properties of normal, variant, and gamma-carboxyglutamic acid modified human factor IX and factor IXa.
    Jones ME; Griffith MJ; Monroe DM; Roberts HR; Lentz BR
    Biochemistry; 1985 Dec; 24(27):8064-9. PubMed ID: 3879187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
    Bertina RM; van der Linden IK; Mannucci PM; Reinalda-Poot HH; Cupers R; Poort SR; Reitsma PH
    J Biol Chem; 1990 Jul; 265(19):10876-83. PubMed ID: 2162822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function.
    Samis JA; Kam E; Nesheim ME; Giles AR
    Blood; 1998 Aug; 92(4):1287-96. PubMed ID: 9694717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling.
    Miyata T; Kuze K; Matsusue T; Komooka H; Kamiya K; Umeyama H; Matsui A; Kato H; Yoshioka A
    Br J Haematol; 1994 Sep; 88(1):156-65. PubMed ID: 7803238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor IX activation by factor XIa proceeds without release of a free intermediate.
    Wolberg AS; Morris DP; Stafford DW
    Biochemistry; 1997 Apr; 36(14):4074-9. PubMed ID: 9100000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavage and activation of human factor IX by serine proteases.
    Enfield DL; Thompson AR
    Blood; 1984 Oct; 64(4):821-31. PubMed ID: 6383497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain.
    Christophe OD; Lenting PJ; Kolkman JA; Brownlee GG; Mertens K
    J Biol Chem; 1998 Jan; 273(1):222-7. PubMed ID: 9417068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
    Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
    Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain.
    McCord DM; Monroe DM; Smith KJ; Roberts HR
    J Biol Chem; 1990 Jun; 265(18):10250-4. PubMed ID: 2355000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
    Sakai T; Yoshioka A; Yamamoto K; Niinomi K; Fujimura Y; Fukui H; Miyata T; Iwanaga S
    J Biochem; 1989 May; 105(5):756-9. PubMed ID: 2753873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.